Nisa Investment Advisors’s Immunomedics Inc IMMU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-180
| Closed | -$15K | – | 2405 |
|
|
2020
Q3 | $15K | Hold |
180
| – | – | ﹤0.01% | 2075 |
|
|
2020
Q2 | $6K | Sell |
180
-1,240
| -87% | -$36.3K | ﹤0.01% | 2004 |
|
|
2020
Q1 | $19K | Buy |
1,420
+330
| +30% | +$5.55K | ﹤0.01% | 1719 |
|
|
2019
Q4 | $23K | Hold |
1,090
| – | – | ﹤0.01% | 1674 |
|
|
2019
Q3 | $14K | Buy |
1,090
+430
| +65% | +$6.32K | ﹤0.01% | 1708 |
|
|
2019
Q2 | $9K | Hold |
660
| – | – | ﹤0.01% | 1797 |
|
|
2019
Q1 | $13K | Hold |
660
| – | – | ﹤0.01% | 1698 |
|
|
2018
Q4 | $9K | Hold |
660
| – | – | ﹤0.01% | 1690 |
|
|
2018
Q3 | $14K | Buy |
660
+160
| +32% | +$3.79K | ﹤0.01% | 1635 |
|
|
2018
Q2 | $12K | Hold |
500
| – | – | ﹤0.01% | 1694 |
|
|
2018
Q1 | $7K | Sell |
500
-800
| -62% | -$13.1K | ﹤0.01% | 1755 |
|
|
2017
Q4 | $21K | Buy |
1,300
+200
| +18% | +$2.36K | ﹤0.01% | 1544 |
|
|
2017
Q3 | $15K | Hold |
1,100
| – | – | ﹤0.01% | 1626 |
|
|
2017
Q2 | $10K | Sell |
1,100
-400
| -27% | -$2.81K | ﹤0.01% | 1736 |
|
|
2017
Q1 | $10K | Buy |
+1,500
| New | +$7.6K | ﹤0.01% | 1682 |
|
Nisa Investment Advisors's IMMU Position: Q4 2020 in Review
Nisa Investment Advisors sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 180 shares — an estimated $15K sold.
Nisa Investment Advisors first reported a position in IMMU in Q1 2017 and held it in 15 quarters. The position peaked at $23K in Q4 2019. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.
- Nisa Investment Advisors reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
- Nisa Investment Advisors sold 180 Immunomedics Inc shares in Q4 2020, an estimated $15K.
- Nisa Investment Advisors first reported a position in Immunomedics Inc in Q1 2017 and held it in 15 quarters.
- Nisa Investment Advisors's Immunomedics Inc position peaked at $23K in Q4 2019.
- 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.
Based on Nisa Investment Advisors's 13F filing for Q4 2020, filed 25 Jan 2021.